Home > Blog > Full service phase ii cancer trial

1 min read

Successful Full-Service, Randomized Pancreatic Cancer Phase II Trial

Success Stories Oncology Biologics Full-Service

Learn how Veristat’s multidisciplinary team was able to work with the sponsor to solve challenges across numerous areas of this full-service phase II cancer trial. Collaborative efforts led to the sponsor decided not to close the Phase II study upon the recommendation of the Safety Review Committee since the primary endpoint was met and there were no safety concerns.

A clinical-stage biopharmaceutical company approached Veristat in a multi-center, randomized Phase II study of a modified synthetic peptide in patients with exocrine pancreatic cancer. The study aimed to establish the efficacy and safety of combinations of the therapy in patients with stage IV exocrine pancreatic cancer. 

In this piece, learn how Veristat’s multidisciplinary team was able to work with the sponsor to solve challenges across numerous areas including: 
  • Slow recruitment
  • Data cleansing post-MSU
  • Multi-site location, process, and staffing
DOWNLOAD

 

Meet Veristat. Learn More.


 

2 min read

Meet Veristat at BIOSPAIN 2026

Oct 5, 2026  Veristat Events

Where Biotech Innovation Meets the Path Forward

BIOSPAIN 2026: September 29- October 1, 2026 – Bilbao, Spain

Veristat...

2 min read

Meet Veristat at SCOPE Europe 2026

Oct 5, 2026  Veristat Events

Where Clinical Trial Strategy Meets Smarter Execution

SCOPE Europe: October 13-14, 2026 – Barcelona, Spain

Veristat is...